DexCom, Inc. · DXCM · Next earnings

DexCom, Inc. reports Thursday, Feb 11, 2027

DXCM reports after market close with consensus EPS at $0.71 and revenue at $1.38B. Last quarter: Dexcom raises 2026 outlook as G7 15-Day adoption expands

Reports After market close98 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.71 Calendar consensus
Consensus revenue $1.38B Calendar consensus
Report date Feb 11, 2027 Thursday, date estimated
Session After market close 98 days away

Where DXCM left off: FY2026 Q3

Full report

Dexcom raises 2026 outlook as G7 15-Day adoption expands

EPS surprise +8.1% Reported $0.73 vs $0.68
Revenue surprise +1.2% Reported $1.34B vs $1.33B
Stock move +5.6% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised full-year 2026 revenue guidance to $5.20-$5.25 billion and increased operating-margin and adjusted-EBITDA targets to approximately 24% and 32%, respectively.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Pricing pressure in selected markets and competitive actions outside the U.S.
  • Reimbursement timing and variability, including the pending CMS type 2 coverage decision.
  • The CVS PBM contract loss, foreign-exchange effects, and Ireland facility ramp and integration costs.

Questions analysts left open

  • Whether pricing headwinds emerge in the U.S. or overseas.
  • The effect of the CVS PBM contract loss on access and revenue.
  • The timing and magnitude of the CMS type 2 coverage decision and the European distributor acquisition.

Ask FN2 about DXCM next report

Transcript, numbers and history already loaded
What should I watch for in DXCM's next earnings report?How did DXCM guide last quarter, and is consensus above or below that?Give me the bull and bear case going into DXCM earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the DXCM recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent DXCM quarters

All DXCM earnings
+5.6%FY2026 Q3+12.0%FY2026 Q2+3.0%FY2026 Q1+7.6%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.